www.patreon.com/Eternaldurdles ALKEM GEAR BAGS! https://www.alkemgear.com/?ref=qhbtohkf When should you actually play Cores in Sorcery: Contested Realm? Cores give you a powerful mana advantage,…

Durable backpacks, messenger bags, dice trays, and playmat cases for trading card and tabletop players. Preorder the first run, ships after Oct 15.

NEW DELHI, India: A number of prominent Indian companies are scheduled to announce their Q1 results on August 14, with investors and market participants set to track earnings updates from companies including Ashok Leyland, NMDC, Alkem Laboratories, Bharat Dynamics, Voltas and PhysicsWallah. The earnings calendar also includes several other companies reporting their financial performance for the first quarter.

Übersicht über aktuelle und frühere Ergebnisse von Wahlumfragen von INSA zur Bundestagswahl (Sonntagsfrage)

Dividend Stocks News: Alkem Laboratories, PI Industries and 2 more have announced interim dividends in the range of 600-1900 per cent.

Alkem Laboratories Walk In Interview 2025 On 20 July 2025 For QC, QA & Production , Packing Department at Vapi - Gujarat Location. 1. Latest Job Vacancy in Alkem Laboratories Walk In Interview 2025 1. Department: Quality Control – Formulation◾️Position: Officer / Sr. Officer◾️Qualification: M.Sc. / B.Pharm◾️Experience

Alkem Laboratories Walk In Interview 2025 on 6th July 2025 For QC/ QA and Production department at Ankleshwar - Gujarat Location. 1. Latest Job Vacancy in Alkem Laboratories Walk In Interview 2025 (1) Department: Quality Control (Formulation)🔺Position: Officer / Sr. Officer🔺Qualification: M.Sc / B. Pharm🔺Experience: 2 to 6 years🔺Area of Expertise :

In recognition of World ORS Day, a city-wide initiative led by the TSL Foundation and supported by Tetra Pak, Halewood, Kenvue, and Alkem, distributed over 3 lakh Ready-to-Drink (RTD) ORS packs to residents across key cities in West Bengal, Maharashtra and Uttar Pradesh. The campaign aimed to raise awareness about the importance of safe, effective hydration-especially during the monsoon season when waterborne illnesses and immunity-related concerns are at their peak.Tetra Pak marks ORS Day with Ready-To-Drink ORS Distribution Drive Unlike traditional ORS solutions, Ready-To-Drink ORS offers a convenient, pre-mixed format that meets WHO-recommended standards and comes in safe Tetra Pak cartons. This ensures accurate dosage, eliminates the need for clean water or mixing, and makes it easier for people of all ages to stay hydrated-whether recovering from illness or simply navigating daily routines."Hydration is a simple habit that can make a big difference to everyday health," said Saurabh Sinha, Marketing Director, Tetra Pak South Asia. "By making ORS more accessible in a ready-to-drink format, our goal is to help consumers stay prepared, stay healthy, and take better care of themselves and their families."To ensure the message of smart hydration reaches diverse communities, the initiative is being amplified through a comprehensive 360-degree outreach effort. This includes on-ground distribution drives, informative radio segments, and engaging social media content-all designed to educate and empower consumers with practical knowledge about everyday hydration. The focus remains on accessibility and awareness-making sure people understand the value of ORS in maintaining health, especially during vulnerable seasons.The RTD ORS packs were developed by trusted brands: Halewood (ElectroRush), Kenvue (ORSL), and Alkem (ORS Insta), each contributing to the shared goal of making hydration simple, safe, and inclusive."TSL Foundation believes that health equity begins with access," said a TSL Foundation spokesperson. "This initiative is about empowering communities with the tools they need to care for their health-starting with something as fundamental as hydration."The month-long drive culminates on World ORS Day, July 29, reinforcing a simple but important message: staying well-hydrated should be easy, safe, and part of everyday life. Smart Hydration for All: Tetra Pak's Ready-To-Drink ORS Distribution Drive Marks World ORS Day

Rubicon Research Limited has completed the acquisition of Alkem Laboratories' formulations manufacturing facility in Pithampur, Madhya Pradesh in an all-cash deal for Rs. 149 crores. The acquired facility, located in the Special Economic Zone at Pithampur, Madhya Pradesh, is equipped to manufacture steroids, hormones, and high-potency products, including immunosuppressants and oncology medications. The facility was inspected by the U.S. Food and Drug Administration (US FDA) in 2022. With a built-up area of more than 16,000 sq. m. and total plot area of more than 1,25,000 sq. m., the site has potential for future expansion. Besides capacity expansion, the addition of a third formulations manufacturing location strengthens Rubicon's supply chain and adds new manufacturing capabilities for Rubicon in segments like steroids, hormones, and high-potency products.Mr. Parag Sancheti, Chief Executive Officer of Rubicon Research Limited highlighted the importance of this acquisition saying, "This acquisition supports our strategy of expanding our US market presence and complements our development efforts to grow our portfolio of specialty products and drug device combination products. The Pithampur facility increases our ability to manufacture products for regulated markets at scale through a resilient supply chain." Additionally states "As mentioned in our DRHP, our two existing manufacturing facilities in Maharashtra as well as our R&D facilities in India and Canada are also USFDA inspected."About Rubicon Research Rubicon Research Limited is a pharmaceutical formulations company with an expanding portfolio of specialty and drug-device combination products, exclusively focused on regulated markets, particularly the United States. Rubicon's total revenue from operations more than doubled from Rs. 3,135.67 million in Fiscal 2022 to Rs. 8,538.89 million in Fiscal 2024, growing at a CAGR of 62.5%, which, according to Frost & Sullivan, was five times higher than the average of 11 assessed peers, making Rubicon the fastest-growing Indian pharmaceuticals formulations company, among the assessed peers. According to Frost & Sullivan, Rubicon is the only Indian pharmaceutical player among six listed Indian peers assessed that is entirely focused on regulated markets. As of March 31, 2024, Rubicon had 69 active US FDA-approved ANDA and NDA products and, according to Frost & Sullivan, ranked among the top 10 Indian companies by total ANDA approvals from the US FDA in Fiscal 2024, securing 14 approvals that year. Between 2018 and 2023, according to Frost & Sullivan, it also ranked 9th among companies. receiving specialty product approvals in the US, with 8 approvals in that period. Rubicon maintains a strong innovation focus, with revenue expenditure on R&D in Fiscals 2024, 2023, and 2022 representing 13.00%, 18.52%, and 40.15% of revenue from operations, respectively. Frost & Sullivan noted Rubicon's R&D expenses as a percentage of revenue from operations in Fiscal 2024 was 2.5 times higher than the average of Indian peers assessed. Disclaimer Rubicon is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a Draft Red Herring Prospectus (DRHP) dated 31 July 2024 with SEBI. The DRHP is available on the website of SEBI at www.sebi.gov.in, the Company at www.rubicon.co.in and the websites of the Book Running Lead Managers - Axis Capital Limited, JM Financial Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), and SBI Capital Markets Limited at www.axiscapital.co.in, www.jmfl.com, www.iiflcap.com, and www.sbicaps.com, respectively and the websites of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details refer to the Red Herring Prospectus, including the section titled "Risk Factors" of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for any investment decision. This press release is for information only and does not constitute an offer to sell or solicitation to buy securities. This announcement is not being made in and copies of it may not be distributed or sent into the United States, the United Kingdom, Canada, Australia or Japan. The securities of Rubicon Research Limited may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Rubicon Research Limited does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States. Rubicon Research Limited Completes Acquisition of Alkem's Pithampur Manufacturing Unit for Rs. 149 Crores

Alkemin känner de flesta till som föreställningen att det skulle vara möjligt att omvandla oädla metaller till guld. Men på den nyöppnade utställningen på Skoklosters slott får besökaren en bredare…

If you take cholesterol-lowering drugs called statins, you may have noticed a flurry of news coverage since late October about an extensive recall of thousands of bottles of atorvastatin, the generic ...